Well lets hope so PoS i just really want to see some developments & something reach maturity. It's no doubt that Phylogica have something with alot of potential as is highlighted by the numerous partnerships (they don't sign them for fun) & the ability to attract employees over time with such high rankings in their field - i guess the only problem is why have many of them walked on ? hopefully the current board & management structure will stand strong, stay put & carry the company through to finally deliver something of value for shareholders.
I also thought a large part of the up-talk about the $5M placement last year was Ascent Biomedical leading out of NY & the ability they had to attract further investment & line the company up for trade sale ? But not a peep from there in the year since they took their position ... but now we have a new appointment i guess chasing the same objective ?
Past Employess
Chairman - Aki von Roy - Ex President Bristol-Myers Squibb
Director - Dr Mark Pierce - Ex Pfizer Senior VP Clinical Research
Head of Licensing - Dr G Pullen - Ex CSL Comm/Buss Manager
Anyway just frustrated no doubt i see the potential that the appointment offers & more than likely (imo) tied to Phenomicas up-start but i guess really "potential" starts to get a bit worn out. I want developments that will succesfully deliver value to shareholders not just a pretty picture.
PYC Price at posting:
3.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)